lncRNAs dysregulation in monocytes from primary antiphospholipid syndrome patients: a bioinformatic and an experimental proof-of-concept approach

Carlos A. Guzmán-Martín, Yaneli Juárez-Vicuña, Aarón Domínguez-López, Javier González-Ramírez, Luis M. Amezcua-Guerra, Laura A. Martínez-Martínez, Fausto Sánchez-Muñoz

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Background: Antiphospholipid syndrome (APS) is the main cause of acquired thrombophilia where peripheral circulating cells such as monocytes have a key role. Currently, several studies have linked long non-coding RNAs (lncRNAs) in different inflammatory and autoimmune processes, including lupus. However, the role of lncRNAs in antiphospholipid syndrome is unknown, therefore, we aimed to select and measure expression levels of three lncRNAs based on its abundance in monocytes from APS patients. Methods: Selection of lncRNAs candidates were carried out based on its abundance in monocytes and their relationship with Perez-Sanchez miRNA signature by using miRNet 2.0 bioinformatic tool, then lncRNAs expression levels was measured in monocytes by RT-qPCR. Results: This is the first study to report that lncRNAs: FGD5-AS1, OIP5-AS1 and GAS5 are promising candidates for play a role on APS monocytes and they are expressed differently between patients and controls. Conclusions: OIP5-AS1, FGD5-AS1 and GAS5 are downregulated on monocytes from APS patients.

Original languageEnglish
Pages (from-to)937-941
Number of pages5
JournalMolecular Biology Reports
Volume50
Issue number1
DOIs
StatePublished - Jan 2023

Keywords

  • Antiphospholipid syndrome
  • FGD5-AS1
  • GAS5
  • Long noncoding RNAs
  • Monocytes
  • OIP5-AS1

Fingerprint

Dive into the research topics of 'lncRNAs dysregulation in monocytes from primary antiphospholipid syndrome patients: a bioinformatic and an experimental proof-of-concept approach'. Together they form a unique fingerprint.

Cite this